pcDNA3.2 TDP-43 YFP Citations (3)

Originally described in: Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.
Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, Padmanabhan A, Clay-Falcone D, McCluskey L, Elman L, Juhr D, Gruber PJ, Rub U, Auburger G, Trojanowski JQ, Lee VM, Van Deerlin VM, Bonini NM, Gitler AD Nature. 2010 Aug 26;466(7310):1069-75. doi: 10.1038/nature09320. PubMed Journal

---

Articles Citing pcDNA3.2 TDP-43 YFP

Articles
Establishment of chemically oligomerizable TAR DNA-binding protein-43 which mimics amyotrophic lateral sclerosis pathology in mammalian cells. Yamanaka Y, Miyagi T, Harada Y, Kuroda M, Kanekura K. Lab Invest. 2021 Oct;101(10):1331-1340. doi: 10.1038/s41374-021-00623-4. Epub 2021 Jun 15. PubMed
Nuclear RNA binding regulates TDP-43 nuclear localization and passive nuclear export. Duan L, Zaepfel BL, Aksenova V, Dasso M, Rothstein JD, Kalab P, Hayes LR. Cell Rep. 2022 Jul 19;40(3):111106. doi: 10.1016/j.celrep.2022.111106. PubMed
Astrocytic TDP-43 dysregulation impairs memory by modulating antiviral pathways and interferon-inducible chemokines. Licht-Murava A, Meadows SM, Palaguachi F, Song SC, Jackvony S, Bram Y, Zhou C, Schwartz RE, Froemke RC, Orr AL, Orr AG. Sci Adv. 2023 Apr 21;9(16):eade1282. doi: 10.1126/sciadv.ade1282. Epub 2023 Apr 19. PubMed

If you have published an article using this material, please email us at to have your article added to this page.